Mental Retardation |
2014-000647-32: A medical treatment trial investigating whether degarelix decreases the risk of persons with pedophilic disorder from committing sexual child molestation |
|
|
| Ongoing | 2 | 60 | Europe | Powder and solution for solution for injection, FIRMAGON | Karolinska University Hospital, Karolinska University Hospital | Pedophilia acccording to DSM-5 (F65.4), Men suffering from pedophilia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2014-001541-24: Neuroenhancement of Interpersonal Psychotherapy in Major Depression Augmentation von Interpersoneller Psychotherapie durch D-Cycloserin |
|
|
| Ongoing | 2 | 28 | Europe | Cycloserin-Kapseln, Capsule, hard, Cycloserine | University Medical Center Freiburg, University Medical Center Freiburg | Major Depression (ICD-10; F32.2/F33.2) Depressive Störung (ICD-10; F32.2/F33.2), Disorder in which the fundamental disturbances are a change in affect or mood to depression and a usually accompanied change in the overall level of activity. Störung deren Hauptsymptome eine Veränderung der Stimmung oder der Affektivität zur Depression hin und eine Veränderung des allgemeinen Aktivitätsniveaus sind., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Not yet recruiting | 2 | 172 | Europe | bumetanide, bumetanide, Tablet, Bumetanide | UMC Utrecht, Dutch Brain Foundation | Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Epilepsy, Autism, ADHD, Epilepsy, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-001567-37: Efficacy of dexmedetomidine for conscious sedation during dental treatement of uncooperative patients with intellectual disability and fear of dentists. |
|
|
| Ongoing | 2 | 30 | Europe | Solution for injection, Dexdor | University Medical Center Groningen, University medical Center Gronignen | dentophobia intellectual disability, Fear of dentist Intellectual disability, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001739-38: A study to evaluate the safety and tolerability of TAK-831 in patients with schizophrenia. |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-831, Tablet | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-000645-48: Cystadane in the treatment of AGU Cystadane AGU-taudin hoidossa |
|
|
| Ongoing | 2 | 15 | Europe | Oral powder, Cystadane anhydrous | Minna Laine, Prof. Ritva Tikkanen, Orphan Europe SARL | Aspartylglucosaminuria Aspartyyliglukosaminuria, Aspartylglucosaminuria (AGU) is a progressive disease that results in severe mental retardation of the patients. The main symptom of the disease is the progressive loss of mental capabilities. Aspartyyliglukosaminuria (AGU) on vaikeaa kehitysvammaisuutta aiheuttava, etenevä lastenneurologinen tauti. Taudin pääoire on henkisen kehityksen taantuminen., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
2016-004973-42: This study tests whether BI 409306 prevents patients with a specific type of mental illness (attenuated psychosis syndrome) from becoming worse. This study looks at how well patients tolerate the medicine and how safe and effective it is over 1 year. |
|
|
| Not yet recruiting | 2 | 300 | Europe | BI 409306, BI 409306, Film-coated tablet | Boehringer Ingelheim Limited, Boehringer Ingelheim Limited | attenuated psychosis syndrome, attenuated psychosis syndrome, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-002232-16: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression |
|
|
| Not yet recruiting | 2 | 90 | Europe | TAK-653, TAK-653, Tablet | Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd | Treatment Resistant Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-004710-95: Extended-release injectable suspension naltrexone (XR-NTX) as an adjunct pharmacotherapy for prevention of drug use in patients with substance use disorder in treatment for ADHD |
|
|
| Not yet recruiting | 2 | 128 | Europe | Naltrexone, Injection, vivitrol | Beroendecentrum Stockholm, Beroendecentrum Stockholm, Alkermes, Swedish research council, Swedish research council for health, working life and welfare | Amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder), Patients who fulfil DSMIV/5 criteria for amphetamine dependence and ADHD (Attention-Deficit/Hyperactivity Disorder), respectively, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-000445-39: A study comparing the safety and clinical effects of different formulations of a new vaccine, ACI-24 with placebo in patients with mild Alzheimer's disease |
|
|
| Ongoing | 2 | 45 | Europe | ACI-24, ACI-24, Suspension for injection | AC Immune SA, AC Immune SA | Alzheimer's Disease, Alzheimer's Disease, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001212-30: A trial to study effects of a single dose Citalopram on emotion processing in patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals |
|
|
| Ongoing | 2 | 30 | Europe | Film-coated tablet, Citalopram | Central Institute of Mental Health, represented by commercial and administrative Director, Boehringer Ingelheim Pharma GmbH & Co KG | Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-004745-70: Efficacy of ketamine nose-spray on acute suicidal thoughts and behaviour Effectiviteit van ketamine-neusspray op acute suïcidale gedachten en gedrag |
|
|
| Ongoing | 2 | 128 | Europe | ketalar, Nasal spray, solution in single-dose container, Ketalar | Academic Medical Center (AMC), Academic Medical Center | Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours. Acute suïcidaliteit, gedefinieerd als een snelle toename in suïcidale gedachten of gedrag vanaf de 'baseline' van patiënt., Acute suicidality, thoughts about the wish to kill oneself, or behaviour with either the aim to die or a significant likelyhood that one could die because of this behaviour. Acute suïcidaliteit, gedachten over de wens zichzelf van het leven te willen beroven, of gedrag met het doel te sterven of met een grote waarschijnlijkheid dat men als gevolg van het gedrag sterft, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-001166-42: Clinical research study to determine how "trazodone" can influence the sleep and how it works in the body after one or repeated doses taken by mouth, in children suffering from insomnia and with autism, intellectual disability or attention deficit hyperactivity disorder (ADHD) Estudio de investigación clínica para evaluar cómo puede influir la trazodona sobre el sueño, así como su funcionamiento en el cuerpo tras una o varias dosis tomadas por boca, en niños que sufran insomnio y autismo, discapacidad intelectual o trastorno por déficit de atención con hiperactividad (TDAH) |
|
|
| Ongoing | 2 | 36 | Europe | trazodone hydrochloride, 152PO17433, Oral drops, solution | Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.), AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A., Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.), AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. | Insomnia in children and adolescents with autism, intellectual disability or ADHD Insomnio en niños y adolescentes, con autismo, discapacidad intelectual o TDAH, Insomnia in children and adolescents with autism, intellectual disability or ADHD Insomnio en niños y adolescentes, con autismo, discapacidad intelectual o TDAH, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-001884-21: Antidepressant trial of a novel P2X7 receptor blocker JNJ-54175446. |
|
|
| Not yet recruiting | 2 | 142 | Europe | JNJ-54175446, JNJ-54175446, Capsule, hard | Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge, Wellcome Trust, Janssen Pharmaceutica NV | Major depressive disorder with an incomplete response to monoaminergic antidepressants and with biomarker profile indicative of inflammation, People with: - major depressive disorder whose condition has not improved with the current antidepressant medications.- increased levels of inflammation., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-000014-38: A Phase IIa Study to Determine the Safety, Tolerability and Efficacy of a daily oral dose of THX-110 in Adult Patients with Tourette Syndrome (TS) |
|
|
| Not yet recruiting | 2 | 60 | Europe | THX-110 [Dronabinol], THX-110 [PEA (Palmitoylethanolamide)], Capsule, soft, Tablet, Dronabinol Capsules, USP | Therapix Biosciences Ltd., Therapix Biosciences Ltd. | Tourette Syndrome, Neuropsychiatric disorder characterized by multiple motor or vocal tics., Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-001683-29: A study to explore the efficacy JNJ-61393215 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 218 | Europe | JNJ-61393215, 45-mg, Capsule, hard | Janssen-Cilag International NV, Janssen Research and Development, LLC | Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants, Major depression with anxiety, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001696-36: Study of efficacy of low-dose interleukin-2 in alteration of the immune system associated with depression Studio di efficacia dell’interleuchina-2 a basso dosaggio nelle alterazioni del sistema immunitario associate alla depressione |
|
|
| Not yet recruiting | 2 | 36 | Europe | Aldesleuchina, [Aldesleuchina], Powder for solution for injection | OSPEDALE SAN RAFFAELE, Unione Europea H2020 –SCI 2016-2017 | Depressive episode in course of mood disorder Episodio depressivo in corso di disturbo dell’umore, Depressive episode in course of mood disorder Episodio depressivo in corso di disturbo dell’umore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001084-20: An experimental trial to investigate a new medicine (drug), TAK-041, in patients with schizophrenia |
|
|
| Not yet recruiting | 2 | 32 | Europe | TAK-041, Powder for oral suspension | Takeda Development Centre Europe Ltd., Takeda Development Centre Europe Ltd. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002106-52: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease |
|
|
| Not yet recruiting | 2 | 40 | Europe | Cannabidiol, Capsule, hard | King's College London, South London and Maudsley NHS Foundation Trust, King's Health Partner's R&D Challenge Funds, Psychiatric Research Trust, Rosetrees' Trust | Alzheimer's disease patients with BPSD, Alzheimer's disease patients with behavioural and psychological symptoms e.g. anxiety, agitation, hallucinations and delusions, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2019-000695-41: A clinical study to explore the efficacy of JNJ-67953964 in the treatment of depression |
|
|
| Not yet recruiting | 2 | 180 | Europe | JNJ-67953964-AAA, Capsule | Janssen-Cilag International NV, Janssen Research and Development LLC | Major Depressive Disorder, depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002708-15: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients WithSchizophrenia With Prominent Negative Symptoms |
|
|
| Not yet recruiting | 2 | 240 | Europe, RoW | Lu AF11167 modified-release tablet, Modified-release tablet | H. Lundbeck A/S, H. Lundbeck A/S | schizophrenia with persistent prominent negative symptoms, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003573-97: A Trial of Psilocybin in Clinical Depression Resistant to Standard Treatments |
|
|
| Not yet recruiting | 2 | 60 | Europe | Psilocybin, Capsule | King's College London, South London & Maudsley NHS Foundation Trust, National Institute for Health Research Clinician Scientist Fellowship Programme (CS-2017-17-007) | Major depressive disorder, Clinical depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000094-24: A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia |
|
|
| Ongoing | 2 | 576 | Europe, RoW | Risperidone, MK-8189, Tablet, Capsule, Risperdal (Risperdione) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-001621-27: A study on ketamine as a treatment for depression and demoralization in patients with advanced cancer Een studie naar het effect van ketamine als behandeling voor depressie en demoralisatie bij patiënten met gevorderde kanker |
|
|
| Not yet recruiting | 2 | 10 | Europe | Solution for injection, Ketanest-S | University Medical Center Groningen, University Medical Center Groningen | Major depressive disorder Depressie, Depression Depressie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000437-41: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients with treatment-resistant schizophrenia (TRS). Studio multicentrico pilota, in aperto, randomizzato, per valutare sicurezza, tollerabilità ed efficacia preliminare in tre gruppi paralleli con tre dosi fisse di Evenamide somministrate come terapia aggiuntiva a pazienti affetti da schizofrenia resistente al trattamento (TRS). |
|
|
| Not yet recruiting | 2 | 150 | Europe | Evenamide, [NW-3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA | Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000439-32: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication. Studio di estensione in aperto, multicentrico per valutare sicurezza, tollerabilità ed efficacia preliminare a lungo termine di evenamide come terapia aggiuntiva in pazienti affetti da schizofrenia resistente al trattamento (TRS) che non rispondono adeguatamente al farmaco antipsicotico attualmente in corso |
|
|
| Not yet recruiting | 2 | 150 | Europe | Evenamide, [NW-3509], [NE-3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA | Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002813-20: A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder |
|
|
| Not yet recruiting | 2 | 240 | Europe | Brexpiprazole, OPC-34712, Tablet | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Borderline Personality Disorder, Borderline Personality Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000350-26: A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLUTION study). Ensayo clÃnico para evaluar la eficacia de vafidemstat en sÃntomas negativos y deterioro cognitivo asociado a la esquizofrenia. (Estudio EVOLUTION). |
|
|
| Ongoing | 2 | 100 | Europe | Vafidemstat, ORY-2001, Capsule, hard | Oryzon Genomics, S.A., Oryzon Genomics, S.A. | Schizophrenia Esquizofrenia, Schizophrenia Esquizofrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-004752-16: A Study to Evaluate the Effects of RO6889450 (Ralmitaront) in Patients with Schizophrenia or Schizoaffective Disorder and Negative Symptoms Estudio para evaluar los efectos de RO6889450 (Ralmitaront) en pacientes con esquizofrenia o trastorno esquizoafectivo y síntomas negativos |
|
|
| Ongoing | 2 | 220 | Europe, RoW | ralmitaront, RO6889450, Capsule, hard | F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Schizophrenia or schizoaffective disorder esquizofrenia o trastorno esquizoafectivo, Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in hallucinations, delusions, and disordered behavior that impairs daily functioning Esquizofrenia: trastorno mental grave en el que las personas interpretan la realidad de forma anormal y puede resultar en alucinaciones, delirios y comportamiento desordenado que afecta el func diario, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002577-22: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression |
|
|
| Not yet recruiting | 2 | 20 | Europe | Psilocybin 5 mg, Capsule | COMPASS Pathfinder, Limited, COMPASS Pathfinder, Limited | treatment resistant depression, treatment resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000867-65: Investigation of the adhesion properties of a newly developed rotigotine-containing patch in patients with Parkinson's disease |
|
|
| Not yet recruiting | 2 | 38 | Europe | ROT-TDS 8 mg/24 h, Neupro® 8 mg/24 h, Transdermal patch, Neupro® 8 mg/24 h | Luye Pharma Switzerland AG, Luye Pharma Switzerland AG | Idiopathic Parkinson's disease, Idiopathic Parkinson's disease, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000805-26: MDMA-Assisted Psychotherapy for the Treatment of Depression |
|
|
| Not yet recruiting | 2 | 12 | Europe | 3,4-methylenedioxymethamphetamine hydrochloride/MDMA HCl /Capsule Active substance: 42542-10-9/3,4-M, Capsule | Østfold Hospital Trust, South-Eastern Norway Regional Health Authority, MAPS PBC | Major Depressive Disorder, Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-000319-21: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial)” |
|
|
| Not yet recruiting | 2 | 189 | Europe | Clonidinhydrochlorid, Doxazosinmesilat, Capsule, hard, Clonidin-ratiopharm® 75, Doxazosin STADA® 1mg Tabletten, Doxacor® 2 mg, Tabletten | Charité – Universitätsmedizin Berlin, Federal Ministry of Education and Research (BMBF) | Posttraumatic Stress Disorder Posttraumatische Belastungsstörung, Posttraumatic Stress Disorder Posttraumatische Belastungsstörung, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-003369-16: An irregular trial in which the identity of those receiving the intervention in twin groups is concealed from both the administrators and subject until the test is completed. The trial is to check the safety and efficacy of GWP42003-P versus Placebo as a joining therapy in Participants with Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment. Un ensayo irregular en el que la identidad de quienes reciben la intervención en grupos gemelos se oculta tanto a los administradores como al sujeto hasta que se completa la prueba.El estudio es para investigar la seguridad y la eficacia de GWP42003-P frente a placebo como tratamiento complementario en participantes con esquizofrenia que experimenten respuesta inadecuada al tratamiento con antipsicóticos en curso. |
|
|
| Not yet recruiting | 2 | 366 | Europe | Cannabidiol (CBD), GWP42003-P, Oral solution, CBD-Oral Solution, is known as Epidyolex, and is the approved name in the EU | GW Research Ltd., GW Research Ltd | Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk of death from a range of comorbid somatic conditions and suicide, the former attributable to unhealthy lifestyle, predisposition, and antipsychotic medication. Individuals typically smoke, can be overweight or obese, suffer from hypertension, dyslipidemias, metabolic syndrome, and diabetes. Esquizofrenia es un síndrome del neurodesarrollo resultado de alteraciones graduales en la conectividad cerebral.Puede persistir durante años antes de que surja la psicosis.El riesgo de muerte es de 2 a 3 veces mayor debido a una variedad de afecciones somáticas comórbidas y suicidio,el primero atribuible a un estilo de vida poco saludable,predisposición y medicamentos antipsicóticos. Las personas suelen fumar,tener sobrepeso u obesidad, hipertensión,dislipidemias,síndrome metabólico ydiabetes, schizophrenia is a severe long-term mental health condition. It causes a range of different psychological symptoms. La esquizofrenia es una afección grave de salud mental a largo plazo. Causa una variedad de síntomas psicológicos diferentes, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-004790-31: A Clinical Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression Estudio para analizar la eficacia, la seguridad y la tolerabilidad de JNJ-55308942 en el tratamiento de la depresión bipolar |
|
|
| Ongoing | 2 | 164 | Europe | JNJ-55308942, JNJ-55308942, Capsule | Janssen-Cilag International NV, Janssen Research & Development, LLC | Bipolar Depression Depresión Bipolar, Depression Depresión, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003164-27: Evaluation of Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients Evaluatie van veiligheid, farmacodynamiek en farmacokinetiek van TW001 in Alzheimer patiënten |
|
|
| Ongoing | 2 | 150 | Europe | TW001 granules for oral solution, TEST, Granules for oral solution | Treeway TW001AD B.V., Treeway TW001AD B.V. | Alzheimer´s Disease (AD) Ziekte van Alzheimer, Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. De ziekte van Alzheimer is een hersenaandoening die langzaam het geheugen en de denkvaardigheden vernietigt, en uiteindelijk het vermogen om de eenvoudigste taken uit te voeren., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-006861-39: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode |
|
|
| Not yet recruiting | 2 | 15 | Europe | 5-MeO-DMT 6,12 and 18mg powder in vial for reconstitution, GH001, Inhalation vapour, solution | GH Research Ireland Limited, GH Research Ireland Limited | Bipolar II Disorder, Form of mental illness where patients experience major depressive episodes and at least one hypomania episode., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
CLIN-011, NCT04739423: A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders |
|
|
| Active, not recruiting | 2 | 41 | Europe, RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia | 07/22 | 07/23 | | |
2021-006879-42: A phase 2 clinical trial of GH001 in patients with postpartum depression |
|
|
| Not yet recruiting | 2 | 15 | Europe | 5-MeO-DMT 6, 12, 18mg, powder in vial for reconstitution, GH001, Inhalation vapour, solution | GH Research Ireland Limited, GH Research Ireland Limited | Post-Partum Depression, Depression associated with pregnancy and childbirth, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-005596-39: Long-term follow-up of safety and effectiveness of MDMA-assisted therapy for posttraumatic stress disorder Dlouhodobé sledování bezpečnosti a persistence MDMA-asistované terapie k léčbě posttraumatické stresové poruchy |
|
|
| Not yet recruiting | 2 | 37 | RoW | 3,4- methylenedioxymethamphetamine hydrochloride, MDMA HCI, Capsule | MAPS Europe B.V., MAPS Europe B.V. | post-traumatic stress disorder (PTSD) Posttraumatická stresová porucha (PTSP), post-traumatic stress disorder, PTSD, Trauma Posttraumatická stresová porucha, PTSP, Trauma, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-006200-33: A Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD) Kliininen tutkimus, jossa arvioidaan psilosybiiniavusteisen psykoterapian tehokkuutta ja turvallisuutta aikuisilla, joilla on alkoholinkäytön häiriö (AUD) |
|
|
| Not yet recruiting | 2 | 160 | Europe | Psilocybin capsule 25 mg, Capsule | Clairvoyant Therapeutics Inc., Clairvoyant Therapeutics Inc. | Alcohol use disorder (AUD), Alcohol use disorder (AUD), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000580-52: A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia |
|
|
| Not yet recruiting | 2 | 600 | Europe | Emraclidine, CVL-231, Tablet | Cerevel Therapeutics, LLC, Cerevel Therapeutics, LLC | Patients with schizophrenia who are experiencing an acute exacerbation of psychosis, Schizophrenia is mental disorder that exhibits problems with positive symptoms (e.g. hallucinations), negative symptoms (e.g. lack of motivation) and cognitive deficits (e.g. information processing)., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-005457-25: Study to assess the safety and efficacy of PCN-101 in treatment-resistant depression |
|
|
| Not yet recruiting | 2 | 93 | Europe | R-ketamine hydrochloride, PCN-101, Concentrate for solution for infusion | Perception Neuroscience, Inc, Perception Neuroscience, Perception Neuroscience, Inc. | Treatment-resistant depression, Treatment-resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000574-26: A randomized, double-blind, placebo-controlled, Phase 2b trial of GH001 in patients with treatment resistant depression |
|
|
| Not yet recruiting | 2 | 80 | Europe, RoW | GH001, GH001, Inhalation vapour, liquid | GH Research Ireland Limited, GH Research Ireland Ltd. | Treatment-resistant depression (TRD), Depression that has not improved with other treatments., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-006233-19: Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study |
|
|
| Not yet recruiting | 2 | 60 | Europe | COMP360, Capsule | COMPASS Pathfinder Limited, COMPASS Pathfinder Limited | Anorexia Nervosa (AN), Anorexia Nervosa (AN), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003834-34: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia Estudio para evaluar la eficacia, la seguridad y la tolerabilidad del Luvadaxistat en pacientes con deterioro cognitivo asociado a la esquizofrenia |
|
|
| Ongoing | 2 | 308 | Europe | Luvadaxistat, NBI-1065844, Tablet | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Cognitive Impairment Associated With Schizophrenia Deterioro cognitivo asociado a la esquizofrenia, Cognitive Impairment and Schizophrenia Deterioro Cognitivo y Esquizofrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2021-004927-34: Clinical study to investigate the efficacy, safety and tolerability of the test substance Ketamine hydrochloride prolonged release tablets compared to placebo in patients with treatment resistant depression. |
|
|
| Not yet recruiting | 2 | 180 | Europe, RoW | Ketamine Hydrochloride Prolonged Release Tablets, KET01, Prolonged-release tablet | Ketabon GmbH, Ketabon GmbH | Treatment-resistant depression, Treatment-resistant depression is defined as the intake of 2 different anti-depressant medications for a sufficient length of time at an adequate dose without an adequate improvement of the depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-003743-10: Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression |
|
|
| Not yet recruiting | 2 | 225 | Europe | 5-MeO-DMT.Benzoate Dry Powder, BPL-003, Nasal powder in single-dose container | Beckley Psytech Ltd., Beckley Psytech Ltd. | Treatment-Resistant Depression (TRD), Depression that has not improved with other treatments., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 2 | 208 | RoW | 50 mg Cannabidiol (CBD), BodECS BioAbsorb(TM) capsule, Placebo, 100 mg Cannabidiol (CBD) | Bod Australia, Woolcock Institute of Medical Research | Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient, Insomnia Due to Anxiety and Fear, Insomnia Due to Other Mental Disorder | 07/23 | 07/23 | | |
2020-003720-16: Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent |
|
|
| Not yet recruiting | 2 | 195 | Europe | MIJ821, MIJ821, Powder for solution for injection/infusion | Novartis Pharma AG, Novartis Pharma AG | Major Depressive Disorder with suicidal ideation with intent, Major Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT05321498: Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation |
|
|
| Withdrawn | 2 | 60 | NA | XPro1595, INB03/XPro™, XENP1595, Dominant-negative Tumor Necrosis Factor (DN-TNF), Placebo, Matching Placebo | Inmune Bio, Inc. | Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders | 10/23 | 10/23 | | |
NCT05904717: Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder |
|
|
| Recruiting | 2 | 40 | Europe, RoW | PXS-4728 (A), Matching Placebo (B) | Pharmaxis | REM Sleep Behavior Disorder | 09/24 | 01/25 | | |
MINDFuL, NCT05318976: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation |
|
|
| Recruiting | 2 | 201 | Europe, Canada, RoW | XPro1595, INB03/XPro™, XENP1595, DN-TNF, Placebo, Matching Placebo | Inmune Bio, Inc. | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment | 12/24 | 12/24 | | |
NCT05522387: An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease |
|
|
| Active, not recruiting | 2 | 11 | RoW | XPro1595, INB03/XPro™, XENP1595, DN-TNF | Inmune Bio, Inc. | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 05/24 | 09/24 | | |
| Not yet recruiting | 1/2 | 16 | Europe | GH001, Inhalation solution | Gh Research Limited, GH Research Limited | Treatment-resistant depression, Depression that has not responded sufficiently to previous treatment, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |